The intersection of mental health and financial risk management represents one of the most significant frontiers in the modern insurance landscape. Simon Glairy, a distinguished expert in risk assessment and Insurtech innovation, brings a unique perspective to how biological breakthroughs can stabilize a sector currently grappling with the unpredictability of psychiatric claims. By examining the shift from reactive claims management to proactive precision medicine, this discussion explores how identifying objective biomarkers can revolutionize patient outcomes and the financial viability of income protection products. We delve into the logistics of international research partnerships, the destigmatization of mental illness through physiological evidence, and the strategic necessity of investing in upstream prevention to mitigate the leading cause of long-term disability in Europe.
While oncology and cardiology rely on validated biological markers, psychiatry often lacks objective tools for early diagnosis. How would the introduction of blood-based or neuroimaging indicators change clinical workflows, and what specific steps are needed to move psychiatry toward a precision medicine model?
The transition to a precision medicine model in psychiatry hinges on replacing subjective observation with hard, quantifiable data, similar to how we treat a cardiac event or a tumor. Integrating blood-based indicators or neuroimaging into the clinical workflow would allow practitioners to detect disorders long before they escalate into the debilitating crises that lead to lengthy, costly insurance claims. Currently, we lack the reliable criteria for risk stratification that other medical fields take for granted, which leaves both doctors and insurers in a reactive position. To move forward, we must fund collaborative research—like the €250,000 Precision Mind Prize—to validate these biological markers across diverse populations. This scientific foundation is the essential first step to ensuring that “early diagnosis” is not just a goal, but a standardized medical reality that shortens the path to recovery.
Mental health disorders are currently the primary driver of long-term sick leave and disability claims across Europe. How does the current inability to stratify risk impact the design of income protection products, and what metrics should insurers prioritize to manage these costs more effectively?
The volatility of psychiatric risk makes it incredibly difficult to model, which ultimately limits our ability to create well-calibrated and affordable income protection products for the public. Without objective biomarkers, insurers are essentially flying blind, unable to distinguish between different risk profiles or predict the likely duration of a disability claim. We need to prioritize metrics that go beyond simple self-reporting, focusing instead on biological and digital indicators that reflect the actual severity of a physiological condition. By investing in research that turns mental health into a “manageable risk” through better stratification, we can move away from generic policies toward more personalized coverage. This shift is vital because mental health is no longer a peripheral issue; it is a dynamic claims area that weighs heavily on the bottom line of every major European insurer.
Establishing collaborative research efforts between different nations, such as France and the United Kingdom, presents unique logistical and scientific challenges. What are the advantages of pooling international data for psychiatric biomarkers, and how can these partnerships accelerate the timeline from laboratory discovery to practical application?
Pooling international data is a strategic necessity because the complexities of the human brain require a massive, diverse dataset that a single country simply cannot provide on its own. By bridging the gap between French and British research institutions, we can create a scientific partnership commensurate with the sheer scale of the global mental health crisis. This cross-border collaboration allows us to share breakthroughs in real-time, ensuring that a discovery made in a London lab can be validated and applied in clinical settings across continental Europe much faster. The inaugural Precision Mind Prize ceremony in London this April highlights exactly this ambition: to act as a catalyst that unites researchers and startups across borders. When we harmonize our scientific efforts, we significantly reduce the time it takes for a laboratory discovery to become a practical tool that helps a policyholder return to work.
Proving that mental illnesses have physiological origins can significantly alter public perception and patient care. How do biological indicators help in breaking down long-standing social taboos, and what impact does this shift have on how individuals declare and manage their conditions in professional environments?
One of the most profound benefits of precision psychiatry is its power to destigmatize mental illness by demonstrating that these conditions are often rooted in physiological realities rather than “character flaws.” When a patient can point to a neuroimaging result or a specific blood marker, it transforms the conversation from one of shame to one of medical management. This shift is critical in professional environments, where fear of judgment often prevents individuals from declaring their struggles until they reach a breaking point. By breaking down these taboos, we encourage earlier declaration and intervention, which is far more effective than trying to manage a crisis after it has already resulted in long-term leave. Helping people feel comfortable seeking help through objective medical evidence is a cornerstone of any modern health strategy.
Shifting focus from managing claims to investing in upstream risk prevention represents a major strategic pivot for the financial sector. In what ways can precision psychiatry reduce the duration of care, and what long-term benefits does this provide for both the insurer and the policyholder?
The insurer of the future can no longer afford to be a passive observer who simply pays out when things go wrong; we must actively invest in reducing the frequency and severity of the risks we cover. Precision psychiatry reduces the duration of care by matching the right treatment to the right patient immediately, bypassing the long “trial and error” periods that currently characterize psychiatric treatment. For the policyholder, this means a faster return to health and professional stability, avoiding the isolation that often accompanies long-term disability. For the insurer, this upstream investment dramatically lowers the cost of disability claims and income protection benefits over the long haul. Ultimately, when we reduce the time to effective care, we create a more sustainable ecosystem where innovation and progress directly serve the well-being of the individual.
What is your forecast for precision psychiatry?
I believe that by 2030, we will see the first generation of insurance products that are fundamentally built around biological psychiatric markers, moving mental health from an “unpredictable risk” to a core pillar of precision medicine. We are moving toward a world where a simple blood test at a primary care check-up could flag a vulnerability to depression or anxiety, triggering immediate preventative support rather than a three-year disability claim. The €250,000 we are awarding this year is just the beginning of a massive shift in how the financial sector views health innovation. As these biological indicators become standardized, the gap between how we treat physical and mental health will finally close, leading to a more resilient workforce and more stable insurance models worldwide.
